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SURGERY FOR ACQUIRED 
HEART DISEASE 
SURGICAL TREATMENT 
OF PROSTHETIC 
VALVE ENDOCARDITIS 
From 1975 through 1992, we reoperated on 146 patients for the treatment of 
prosthetic valve endocarditis. Prosthetic valve endocarditis was considered to 
be early (< 1 year after operation) in 46 cases and active in 103 cases. The extent 
of the infection was prosthesis only in 66 patients, anulus in 46, and cardiac 
invasion in 34. Surgical techniques evolved in the direction of increasingly 
radical débridement of infected tissue and reconstruction with biologic mate- 
rials. All patients were treated with prolonged postoperative antibiotic therapy. 
There were 19 (13%) in-hospital deaths. Univariate analyses demonstrated 
trends toward increasing risk for patients with active endocarditis and 
extension of infection beyond the prosthesis; however, the only variables with 
a significant (p < 0.05) association with increased in-hospital mortality 
confirmed with multivariate testing were impaired left ventricular funetion, 
preoperative heart block, coronary artery disease, and culture of organisms 
from the surgical specimen. During the study period, mortality decreased from 
20% (1975 to 1984) to 10% (1984 to 1992). For hospital survivors the mean 
length of stay was 25 days. Follow-up (mean interval 62 months) documented 
a late survival of 82% at 5 postoperative y ars and 60% at 10 years. Older age 
was the only factor associated (p = 0.006) with late death. Nineteen patients 
needed at least one further operation; reoperation-free survival was 75% at 5 
and 50% at 10 postoperative y ars. Fever in the immediate preoperative p riod 
was the only factor associated with decreased late reoperation-free survival (p 
= 0.032). Prosthetic valve endocarditis remains a serious complication ofvalve 
replacement, but the in-hospital mortality of reoperations for prosthetic valve 
endocarditis has declined. With extensive débridement of infected tissue and 
postoperative antibiotic therapy, the extent and activity of prosthetic valve 
endocarditis does not appear to have a major impact on late outcome, and the 
majority of patients with this complication survive for 10 years after the 
operation. (J THORAC CARDIOVASC SUkG 1996;111:198-210) 
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p rosthetic valve endocarditis (PVE) is a serious 
complication of cardiac valve replacement. 
Large studies of patients undergoing primary valve 
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replacement have shown that despite the use of 
perioperative antibiotic therapy, the likelihood of 
PVE occurring during the first postoperative year 
has been approximately 3% and after the first 
postoperative years the risk of PVE appears to be 
approximately 1% per year. 1-6 Treatment with anti- 
biotics alone can be an effective therapy for PVE, 
particularly for patients with infection limited to the 
leaflets of a bioprosthesis. However, most patients 
with infection of a prosthetic valve anulus will 
require replacement of the prosthesis in addition to 
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Fig. 1. Number of operations for PVE per year, 1975-1992. 
antibiotic therapy, and many patients with "cured" 
PVE infection will eventually require reoperation. A 
combination of surgery for excision of infected 
tissue and ~alve rereplacement, along with intensive 
long-term antibiotic therapy, has often been success- 
ful in treating patients with PVE, but in-hospital 
mortality rates of reoperations for PVE have been 
22% to 46% even at centers with extensive experi- 
ence in valve surgery. 2'7-12 Furthermore, eradication 
of infection has been inconsistent even with second 
operations, and late survival and reoperation-free 
survival have not been favorable even for patients 
who weather surgery for PVE. 
However, a number of factors may have improved 
the outlook for patients with PVE. Improvements in 
myocardial protection have allowed surgeons to 
perform operations involving extensive débridement 
and complex cardiac reconstructions. The use of 
biologic materials for reconstruction, including aor- 
tic valve homografts, has increased and new gener- 
ations of antimicrobial agents have been used. To 
assess the current status of surgical therapy for PVE, 
we reviewed the case histories of 146 patients who 
underwent reoperation for PVE from 1975 to 1992. 
Inclusion in this study was stopped in 1992 to allow 
at least a 2-year follow-up. 
Pat ients  and  methods  
Pat ient  popu la t ion .  With the aid of a computerized 
cardiovascnlar information registw, we identified all pa- 
tients (n = 146) who underwent a reoperation for the 
surgical treatment of PVE from 1975 through 1992. The 
number of operations performed for PVE during the 
period of the study has increased progressively (Fig 1). 
Although some patients had multiple operations for PVE, 
the operation examined was the first operation for PVE 
done at The Cleveland Clinic Foundation. Variables 
related to the previous operation, interval between oper- 
ations, PVE illness, and the reoperation for PVE were 
examined for the association with early and late risk and 
are listed in Table I and Appendix I. To analyze changes 
in the patient population and effectiveness of treatment, 
patients were subgrouped according to the year of their 
PVE reoperation, 1975 to 1984 versus !985 to 1992. 
Def in i t ions .  Early PVE was defined as a reoperation for 
PVE within 1 year of the previous valve replacement, 
whereas late PVE applied to patients undergoing reopera- 
tion m0re than 1 year after the previous valve replace- 
ment. 
Three criteria were used in the definition of active PVE: 
positive blood cultures within 2 months of operation, 
positive cultures of the surgical specimen removed at 
reoperation, ororganisms identified by microscopic exam- 
ination of the surgical specimen. A total of 103 patients 
fulfilled one of these criteria and were considered to have 
active endocarditis, whereas the remaining 43 were con- 
sidered to have healed endocarditis. 
Regarding extent of infection, patients were sub- 
grouped according to the operative findings of the status 
of the prosthesis, the prosthesis-cardiac anulus interface, 
and the degree of myocardial invasion of infection. The 
patient was considered to have infection of the prosthesis 
only (66 patients) if a significant periprosthetic leak was 
not identified and myocardial invasion was not noted; a 
significant periprosthetic leak without extensive myocar- 
dial invasion was considered to indicate an anulus infec- 
tion (46 patients); and tissue destruction beyond the 
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Table I. In-hospital mortality according to surgicaI period 
1975-1984 
No. % p Value* 
1984-1992 Total 
No. % No. % P value? 
9/44 20 0.079 
Early 4/i1 36 0.046 
Late 5/33 15 0.524 
Active 8/33 24 0.146 
Healed 1/11 9 0.451 
Extent of infection 
Prosthesis alone 2/19 10 0.373 
Anulus 4/17 24 0.397 
Invasive 3/8 38 0.355 
Surgical specimen culture positive 
No 4/29 14 0.071 
Yes 5/15 33 0.483 
10/102 10 19/146 
3/35 9 7/46 15 
7/67 10 12/100 12 0.591 
9/70 13 17/103 16 
1/32 3 2/43 5 0.052 
2/47 4 4/66 O 
3/29 10 7/46 15 
5/26 17 8/34 24 0.04 
2/65 3 6/94 ó 
8/37 22 13/52 25 0.001 
*p Value for comparison f mortality per variable for the two surgical periods. 
tp Value for difference in mortality for each variable for entire patient group. 
prosthesis-tissue interface was considered to indicate in- 
vasive infection (34 patients). Patients with multiple in- 
fected valves were classed aceording tothe valve with the 
most extensive infection. 
In-hospital death (early mortality) was defined as death 
before hospital discharge regardless of the duration of 
hospitalization. Late death was defined as death after 
discharge from the operative hospital stay. 
Results 
Bacteriology and pathology. The organisms iden- 
tified at culture ither of the blood (106 patients) or 
of the surgical specimen (52 patients) are listed in 
Appendix II, separated according to early versus 
late infection. In three patients cultures were nega- 
tive but microscopic examination of the surgical 
specimen revealed the organisms. Examination of 
organisms according to whether they were linked to 
healed or active PVE showed that hea!ed status was 
more common after enterococcal (5/11) and strep- 
tococcal (8/27) infection. On the other hand, PVE 
was considered healed in only three of the 31 cases 
of Staphylococcus aureus PVE and in none of the 
eight cases of fungal endocarditis. 
Pathologic eonditions detected at operation dif- 
fered on the basis of the time of the infection and 
the prosthesis type. Of the 46 patients with early 
PVE, 20 (43%) had infection of the anulus, 18 
(39%) had invasive infection, and only 8 (17%) had 
infection of the prosthesis only. On the other hand, 
of the 100 patients with late PVE, 58 had involve- 
ment of the prosthesis only; 49 of those infections 
involved bioprostheses, 3 homografts, and 6 me- 
chanical valves. Of 71 late infections of bioprosthe- 
ses, 49 (69%) involved the prosthesis only; of 26 
infections involving late mechanical valve PVE only, 
6 (23%) were limited to the prosthesis. Including 
both early and late infections, there were 90 in- 
stances of bioprosthesis infection with involvement 
of the prosthesis only, 53 (95%), annular infection, 
18 (20%), and invasive infection, 19 (21%). For 
patients with infected mechanical valves (n = 54) 
the infections were distributed as follows: prosthesis 
in 10 (18%), anulus in 28 (52%), and invasion in 15 
(28%). The majority of patients (26/49, 53%) with 
late infections of bioprostheses were considered to 
have had healed infections at the time of the oper- 
ation, and the mean interval between the onset of 
PVE and the reoperation was 21 _+ 24 months. 
Operative technique. As surgical experience in- 
creased operative techniques evolved. Except in 
seven patients operated on in the early years of the 
study, cardioplegia was used for myocardial protec- 
tion in all patients, with a trend toward blood 
cardioplegia in more recent years. Progressively 
more radical débridement of cardiac tissues was 
carried out combined with reconstruction f cardiac 
structures with biologic materials, such as autolo- 
gous or bovine pericardium. Valve replacement was 
accomplished with mechanical valves (n = 52), 
bioprostheses (n = 76), and homografts (n = 13). In 
five patients the valve was not rep!aced: four pa- 
tients had repair of a periprosthetic leak and one 
underwent thrombectomy. All patients with active 
PVE were treated with long-term intravenous anti- 
biotic therapy (4 to O weeks after the operation). 
ln-hospital mortality. Nineteen (13%) in-hospi- 
tal deaths occurred. The mode of death was intra- 
operative myocardial failure in four, postoperative 
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myocardial failure in sLx, multisystem organ failure 
in three, persistent sepsis in two, and rnyocardial 
infarction, renal failure, cerebral hemorrhage, and 
pulmonary embolus in one each. Compared accord- 
ing to the surgical periods, the in-hospital mortality 
decreased from 20% (9/44) during the 1975-1984 
period to 10% (10/102) during the 1985-1992 period 
(12 = 0.079). 
Univariate analyses of the association of preoper- 
ative and operative variables with in-hospital mor- 
tality are listed in Table I and Appendix I. For the 
entire duration of the study, the variables with an 
association (p < 0.1) with mortality were preopera- 
tive heart block, surgical specimen culture positive 
for microorganisms, coronary artery disease, preop- 
erative left ventricular function, year of operation, 
active PVE, invasive infection, and fever for 1 to 3 
days before the operation. Inclusion of these vari- 
ables in a logistic regression model identified pre- 
operative heart block (p = 0.0047), positive surgical 
specimen culture (p = 0.0179), coronary artery 
disease (p = 0.0423), and abnormal left ventricular 
function (p = 0.0223) as associated with increased 
in-hospital mortality. 
For some patient subsets, in-hospital mortality 
rates for the 1975-1984 and 1985-1992 time frames 
were compared with univariate testing (see Table I). 
In the more recent ime frame, there was a signifi- 
cant decrease in mortality for patients with early 
PVE and nonstatistically significant trends toward a 
decreased risk for patients with active PVE; pros- 
thesis, anulus, or invasive infection; patients with 
organisms cultured from the surgical specimen; and 
for the enfire group. 
Patients undergoing operation during the 1985- 
1992 period were examined as a separate subset, 
and logistic regression analysis identified preoperative 
left ventricular function ~o = 0.0012) and positive 
culture of the surgical specimen (p = 0.0119) as the 
only factors associated with mortality during that time 
frame. 
Perioperative morbidity included reoperation for 
bleeding in 15 patients (10%), pacemaker place- 
ment in 20 :(14%), renal failure in 10 (7%), respira- 
tory failure in 9 (6%), stroke in 4 (3%), myocardial 
infarction in 2 (1%), and wound infection in 3 (2%). 
For hospital survivors the mean length of hospital 
stay was 25: days. 
Late results. Follow-up at a mean postoperative 
intervat of 62 months documented late survival (sur- 
vival of in-hospital survivors) of 82% at 5 years and 
60% at 10 postoperative y ars (Fig. 2, A). That pro- 
duced an overall survival (including in-hospital de ths) 
of 71% at 5 years and 52% at 10 postoperative y ars. 
Thirty-six late deaths occurred, with the mode of 
death being congestive heart failure (n = 10), undoc- 
umented but probable cardiac death (n = 4), sudden 
death (n = 3), death at cardiac reoperation (n = 3), 
stroke (n = 3), arrhythmia (n = 2), renal failure (n = 
2), and acute myocardial infarction, sepsis, endocardi- 
tis, and bleeding (n = 1 each). Only five deaths were 
clearly not related to heart disease, endocarditis, or 
valve disease. They were caused by ruptured aneurysm 
in two patients, cancer in two, and trauma in one. 
Of the 127 in-hospital survivors of the initial PVE 
operation, 19 had a subsequent valve reoperation. 
The late reoperation-free survival of those 19 pa- 
tients was 76% at 5 postoperative y ars (Fig. 2, B). 
Eight patients Underwent reoperation within 1 year 
of their original PVE operation (three with organ- 
isms identified in the blood or surgical specimen), 
and 11 underwent a second operation more than 1 
year after their original PVE operation, organisms 
being identified in two of those patients. Four of the 
19 patients had a further reoperation, and one 
patient had two more reoperations. For the 19 
patients who required one operation or more after 
the initial operation for PVE, the 5-year survival was 
59% after that second PVE operation. All patients 
with a known recurrence of endocarditis after heir 
PVE operation underwent a second operation. 
Examination of the variables in Table I and 
AppendLx i did not demonstrate a significant differ- 
ence in late survival or reoperation-free survival on 
the basis of the time of the infection (early vs late) 
(Fig. 3), activity of the infection (active vs healed), 
or the extent of the infection at operation (Fig. 4). 
For the entire group of patients, the type of valve used 
for rereplacement did not influence late outcome, and 
evaluation of the patients who underwent reoperation 
for isolated aortic valve PVE did not demonstrate an 
ädvantage for any valve type (Fig. 5). 
Multivariate testing by means of Cox regression 
analysis howed that oniy advanced patient age was 
associated with decreased late survival (p = 0.006). 
Multivariate testing in regard to reoperation-free 
survival showed that only fever in the immediate 
preoperative period (1 to 3 days before the opera- 
tion) was associated with decreased late reopera- 
tion-free survival (p = 0.032). 
Discussion 
The number of patients operated on each year for 
PVE at our institution has been increasing as a 
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Fig, 2. Late survival and reoperation-free survival for the in-hospital survivors f operations for PVE (A) 
and for the 19 patients who underwent subsequent reoperation (B). 
result of multiple influences, including the large 
numbers of patients who now have had successful 
valve replacement and who are at risk for PVE, 
regional referral patterns, and an aggressive attitude 
toward the surgical treatment of patients with PVE. 
Yet even this relatively large single-institution series 
contains only 146 patients distributed over a 17-year 
time frame. In-depth statistical analysis in all studies 
of PVE is difficult because of the small patient 
numbers. Therefore our observations have per- 
tained to some not statistically significant trends, as 
well as statistically significant results of univariate 
and multivariate analyses. 
Bioprostheses and mechanical valves differed with 
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Fig. 3. Early versus late infection did not appear to influence late survival (A) or reoperation-free survival 
(B). 
regard to the type of disease found at reoperations 
for PVE. Patients with late infections of bioprosthe- 
ses frequently had involvement of only the prosthe- 
sis (69%), whereas infection was limited to the 
prosthesis in only 23% of patients with late PVE 
involving a mechanical valve. For both types of 
prostheses, annular and invasive infections predom- 
inated, with only 17% of early infections being 
limited to the prosthesis. 
The bacteriologic haracteristics of the series 
were consistent with previous studies of PVE. 
Gram-positive organisms predominated. Streptococ- 
cus and Enterococcus were common causes of late 
PVE but were not common in the early setting. 
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Patients rarely were reoperated on for "healed" 
PVE if the organisms were Staphylococcus aureus 
(3/31) or fungus (0/8), illustrating the difficulty in 
eradicating these organisms with antibiotic treat- 
ment alone. The majority of patients who underwent 
surgical treatment for healed PVE were patients 
with late infections of bioprostheses, and the caus- 
ative organisms were most likely to be Enterococcus 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 1 
Lytle et al. 205 
> 
. m  
CO 
100 
80 
60 
40 
20 
A 
83.1% 
83.2% 
83.3% 
I 
_ - -  ~.-, - , - , - . - .  ,4 = .- ~ . - i , - . , - , - , - . . - - -  83.3 % 
: I 
58.7 % 
. . . . . . . . . . . . . . . . . . . . . . . .  41 .6  % 
Biological  
..... Mechanical 
. . . .  Homograft 
p=0.88 
0 
I I I I 
2 4 6 8 
Years 
I I 
10 12 
oS. 
> 
> 
"-1 
cO 
100 
80 
60 
40 
20-  
80.5% 
78.9% 
I 
_ "" - t ' " :  . . . . . . . . . . . . . . . . . .  ! ......... 
i_ 
" . . . . . . . . . . . . .  -:"" "64.3% 
I 
I 59.3% 
Bio log ica l  
...... Mechanical 
. . . .  Homograft 
.... . . . . . . . . . . . . . . . . . . . .  39.5% 
p=0.64 
I I I I I I 
B 0 2 4 6 8 10 12 
Years  
Number 38 29 24 20 17 8 7 
at . . . .  12 7 5 1 
Risk ....... 24 19 10 4 3 2 1 
Fig. 5. For patients with aortic valve PVE, late survival (A) and reoperation-free survival (B) were 
equivalent regardless of the type of prosthesis used. 
or Streptococcus. Other authors have noted that this 
subgroup may often be successfully treated with 
antibiotic therapy, at least temporarily. 13However, 
it is also clear that even endocarditis nvolving only 
the bioprosthesis hastens the failure of those valves, 
inasmuch as the interval between the onset of PVE 
and the time of reoperation was just under 2 years in 
our series. 
In-hospital mortality clearly decreased (20% to 
10%) when the two time periods of the study 
(1975-1984 vs 1984-1992) were compared. Although 
the risk for patients in both high- and low-risk 
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subgroups decreased, most notable was the im- 
proved survival for patients in high-risk categories. 
In particular, the decrease in mortality in operations 
for early endocarditis was statistically significant and 
there were strong trends toward a decreased mor- 
tality for patients with active PVE and invasive 
disease. The trend in surgical technique has been 
toward more extensive operations. It is probable 
that effective myocardial protection, as well as in- 
creased surgeon experience, accounts for this im- 
provement in in-hospital risk. 
During the 1984-1992 time frame, our surgical 
technique volved in the direction of more extensive 
débridement of myocardial tissue and the use of 
biologic materials for reconstruction. The fact that 
14% of patients required new pacemaker placement 
is some indication of the extent of tissue removal. 
The specific measures that are necessary to eradi- 
cate infection vary from case to case, and publica- 
tions by Ergin and associates 14 and David 1» have 
illustrated some approaches to specific anatomic 
problems. We have found that division of the supe- 
rior vena cava allows precise exposure of the mitral 
valve and aortic valve and may be extremely helpful 
when bivalvular infection extends to the fibrous 
trigone of the heart. 16 We prefer autologous peri- 
cardium for cardiac reconstruction, but if that is not 
available bovine pericardium has been used with 
suecess .  
The use of aortic valve homografts for the treat- 
ment of aortic valve PVE is another concept that has 
been suggested by multiple investigators. 9' 22. 17-19 
Our use of homografts for this indication began in 
1988. Although we have reported the use of only 13 
homografts in this series, through the middle of 
1994 we have placed another 20 homografts during 
reoperations for PVE. 2° Early series of patients 
receiving homografts for aortic root infections in- 
volving prosthetic valves reported high in-hospital 
mortality rates, 12' 17 but the risk appears to have 
decreased with increased experience, is' 2o 
The presence of PVE injects uncertainty into the 
long-term result of valve replacement, and in the 
past patients have been noted to have had unfavor- 
able rates of late death, recurrence of infection, and 
reoperation. In a study of 49 patients with PVE by 
Larbalestier and associates, 1° 22% died in the hos- 
pital and another 22% died after hospital discharge, 
for a total survival of approximately 50% at 5 years. 
Jault and associates 11 noted a 54% survival at 6 
postoperative y ars with a 26% incidence of reop- 
eration. Calderwood and coworkers g noted a 23% 
in-hospital mortality, with 75% of the survivors of 
combined medical and surgical treatment s ill alive 4 
years after the operation. A more recent series 
reported by David and colleagues 21reviewed 24 
patients with PVE who had a 12.5% in-hospital risk 
and a 56% 5-year survival. Clearly the issue is not 
resolved once the patient leaves the hospital after 
surgery for PVE. 
In this study we found a late survival (survival of 
in-hospital survivors) of 82% at 5 years and, includ- 
ing in-hospital mortality in the calculations, a 5-year 
survival of 71%. Subsequent reoperation was per- 
formed for 15% of in-hospital survivors. It is dilficult 
to know what to compare these results with, because 
late survival after valve reoperation for indications 
other than PVE is not a well-studied subject. Late 
mortality in this series was largely cardiac related, 
although rarely was it clearly related to infection. Of 
the 19 patients who underwent reoperations after 
their PVE operation, there were only five in whom 
active infection was demonstrated as the cause of 
that second operation; two of these infections oc- 
curred 3 or more years after the PVE operation, 
possible xamples of reinfection rather than persis- 
tent infection. These observations may mean that 
the infections were eradicated and that the reopera- 
tions that were needed were engendered by bland 
periprosthetic leaks. However, an alternative expla- 
nation is that persistent infection did cause peripros- 
thetic leaks leading to a second operation but that 
organisms could not be cultured, perhaps because of 
long-term antibiotic therapy. It is our hope that a 
more radical approach to reoperations for PVE will 
result in a higher ate of cure of infection. Realisti- 
cally, although we have shown that in-hospital risk 
has decreased, the late results do not yet seem to 
place patients undergoing reoperation for PVE in a 
"normal" post-valve replacement survival mode. 
We did not document an improvement in late 
survival on the basis of surgical period. However, 
there were trends toward older age and an increased 
prevalence of coronary artery disease for patients in 
the more recent surgical period, alterations in the 
patient population that may have blunted the influ- 
ence of improved surgical results. It is noteworthy 
that the time of infection (early vs late), the activity 
of the infection, and the extent of the infection at 
reoperation did not influence late survival or late 
reoperation-free survival. We would like to think 
that this occurred because aggressive reoperation 
eradicated the infection more orten and improved 
the survival of those patients in high-risk categories. 
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Other authors have presented evidence that the 
use of aortic valve homografts in the treatment of 
PVE improves long-term outcome] 2' 18 We believe 
this may be true, and we currently use aortic valve 
homografts in the treatment of patients with aortic 
valve and aortic root infection. However, the data 
from this study do not demonstrate an improved 
long-term outcome for the small numbers of pa- 
tients who did receive homografts. Furthermore, 
with extensive débridement at reoperation and the 
use of intensive long-term antibiotic therapy, valve 
rereplacement for PVE with standard prostheses i
not a futile gesture, inasmuch as patients undergo- 
ing reoperation with bioprostheses and mechanical 
valves had a late 5-year survival of 83%. 
Finally, persistence appears to be of value in the 
treatment of PVE. For the 19 patients who required 
one or more reoperations after their PVE opera- 
tion, survival was still 59% at 5 postoperative y ars. 
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Discussion 
Dr. D. Craig Miller (Stanford, Calif.). I agree with you, 
Dr. Lytle, that if you use a tissue valve the infection tends 
not to be as invasive as with a mechanical valve. That leads 
to a more general question, which I admit is not the topic 
of your paper: If a biologic valve becomes infected, is the 
infection more likely to be successfully eliminated with 
medical therapy alone than would an infection affecting a
mechanical valve? 
Dr. Lytle. I think the infection is more likely to be 
208 Lytle et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1996 
controlled. A very common scenario, however, was that 
when we reoperated for patients who had a heäled 
infection, it was usually a leaflet infection on a biopros- 
thesis that was treated successfully with antibiotics; then 
usually within 1 to 2 years (the mean interval between 
treatment and operation was 21 months), these biopros- 
theses had to be operated on. These valves orten can be 
treated successfully and can be sterilized, but their fäilure 
rate is accelerated by the occurrence of endocarditis. 
Dr. Miller. You do not mind substituting an old healed 
case of PVE for an active one, do you? 
Dr. Lytle. i think operating on healed PVE is preferable 
to operating on active PVE. 
Dr. Miller. Agreed. Second, I think you might have 
tilted the playing field in your definition of early PVE, 
which you defined as 1 year postoperatively. If I remember 
correctly, the infectious disease group at The Massachu- 
setts General Hospital and the Mayo Cliriic, as well as the 
Alabama cardiovascülar surgeons and our group at Stan- 
ford, have all come up with a fairly generally promulgated 
definition of 3 months. Would early versus late become or 
emerg e as more significant had you used the more con- 
ventional definition of early PVE? 
Dr. Lytle. I don't know. We did that because mosl 
infections occur within the first year. We did not review 
the orgänisms that were involved, but in our experience 
infections developing Within 1 year of operation were 
most orten nosocomial infections that were acquired at 
the time of the hospitalization. Eren if the infeetion takes 
6 or 8 months to develop, the distribution ofthe organisms 
is more characteristic of early than late infections. 
When we looked at the onset of early PVE according to 
month, most infections occurred in the first 6 months. I do 
not agree that 3 months is the correct ime to designate as 
an early infection. I think 6 months is reasonable, but the 
reason we chose 1 year is that at 1 year the incidence 
appeäred to decrease. I'he incidence was low between 1 
year and 18 months to 2 years after operation. 
Dr. Miller. I am surprised that the organism did not 
emerge as an important factor. In North America. Staph- 
ylococcus epidermidis did not emerge as strongly as Staph- 
ylococcus aureus did in the previous Brisbane series. Do 
you have any comments regarding that? 
Dr. Lytle. Pathologic haracteristics differed according 
to the organism. We had no cases of healed PVE when 
fungal organisms were involved, and of 31 cases of Staph- 
ylócoccus aureus PVE, only three were considered to be 
healed. However, I believe the reason that those were not 
risk fäctors for either early or late death is that we were 
extremely aggressive in cutting oul the infection. 
Dr. Miller. That leads right into my next question. You 
failed to show a demonstrable salutary effect of ho- 
mografts. You did mention that this might be due to the 
small number of patients with homografts (the studies 
stopped in 1992); alternatively, could it be the skewed 
distribution of early versus late or active versus healed 
PVE? Data from Brisbane, Australia, indicate that a 
homograft valve re-replacement eliminates the high 
early-phase hazard but has no real salutary effect on the 
late constant hazard of PVE. This leads me to the cases of 
fungal valve endocarditis. What would you do today? Is 
there any doubt hat a homograft aortic root replacement 
is the best course of action? 
Dr. Lytle. We have written a separate article that deals 
specifically with fungal endocarditis, and we do believe 
that a homograft is important. Our best results with fungal 
endocarditis, and we have only about 14 cases, have been 
with the use of a homograft, reatment with amphotericin, 
and lifelong treatment with oral azole agents. 
This leads to another point--the concept of long-term 
oral suppressive therapy. That is critical in patients with 
fungal endocarditis. Some of our patients with fungal 
endocarditis have done well for years, stopped taking their 
oral antifungal agents, had recurrent fungal endocarditis 
at that time, undergone a reoperation, and been all right 
after the second operation. With fungal endocarditis, the 
optimal treatment is to use a homograft and to prescribe 
antibiotics forever. 
Whether that also applies to bacterial endocarditis 
hard to say. One of the problems, particularly for methi- 
cillin-resistant Staphylococcus, i  the lack of availability of 
a good oral agent, Also, we tend not to have cultured 
organisms from patients having reoperations for late 
PVE. However, I think the plan for fungal endocarditis in
the aortic position ought to be a homograft aortic valve 
replacement and lifelong antifungal therapy. 
Dr. Miller. I agree. Inasmuch as we share your di- 
lemma, how do you differentiate between recurrent and 
residual PVE postoperatively? We have used a simple 
definition: If it is the same organism, it is probably 
residual; if it is a different organism, it is recurrent. What 
is your opinion? 
Dr. Lytle. It is difficult to make the distinction. We had 
an early phase, within 1 year of the operation for PVE, in 
which a couple of patients had positive cultures. Then 
there were some late cases of PVE, only one or two of 
which had positive cultures. Thus I do not know how to 
distinguish between recurrent and reacquired infection. 
That is the reason that we dealt with reoperation rather 
than documented recurrence of an infection. It may be 
that for many of these patients operated within 1 year the 
need for reoperation is generated by persistent infection 
that we are unable to detect. 
Our answer to the whole question of PVE is that we are 
just getting more comfortable with radically débriding the 
infected tissue. Following the principles of cutting out the 
infection, closing the holes, and replacing the valve seems 
to work pretty well. 
Dr. Augustin Arbulu (Detroit, Mich.). You say that 
reoperation is not futile in this group of patients, and I do 
agree with you, but I would like a clarification. Are you 
including in this statement persons who are addicted to 
drugs and are actively using drugs? 
Dr. Lytle. We do not have a large population of persons 
addicted to drugs in our care. We do have some anecdotal 
experience. The combined medical-social spects of that 
problem have worked out favorably in about half of these 
patients on whom we have operated. 
Dr. Arbulu. In my experience, as reported in one of my 
previous publications, reoperation is a futile exercise in 
persons addicted to drugs who are continuing to use the 
drugs, 
You suggest that the homograft may be the answer in 
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fungal endocarditis. On the basis of my experience, I do 
agree with you that in fungal endocarditis antifungal 
treatment should be for life, but what is the basis for your 
enthusiasm with regard to homografts and fungal endo- 
carditis? 
Dr. Lytle. We have operated on eight patients with 
fungal endocarditis and aortic root infections, and three of 
those patients had infection of the aortic root and some 
sort of ascending aortic graft. All of those patients are 
currently alive without reoperation, except for one who 
had a fungus that was insensitive to every antibiotic that 
we tried, both in vitro and in the patient. Thus among the 
seven patients who had a fungal infection for which we 
had an antifungal agent, there have been no recurrences. 
I think that it is encouraging enough to warrant nur use of 
this type of therapy. 
Dr. Arbulu. Are they receiVing antifungal agents cur- 
rently? 
Dr. Lytle» Yes, they will all be taking azul agents orally 
forever. 
Dr. Arbulu. I sliare that enthusiasm when we use a 
mechanical prosthesis in valve replacement for fungal 
PVE, The problem in nur experience is that as we 
approach the fifth year of follow-up all of the patients die. 
It will be interesting to see what happens in your series. 
Dr. Glenn D. Pennington (St. Louis, Mo.). Dr. Lytle, 
you indicated that many of these operations involved 
extensive débridement and then reconstruction. You men- 
tioned using Peri-Gard vascular graft material (Bio-Vas- 
cular, St. Paul, Minn.), but do you have a preference for 
material? Do you use cryopreserved h0mograft? Is there 
any relationship to infection? 
Dr. Lytle. My personal choice is autologous pericar- 
dium. If the patient has been operated on a number of 
times, there will not be rauch autologous tissue left, nr the 
infection may extend into the pericardium. Those are the 
circumstances under which we have used Peri-Gard vas- 
cular graft material. We have not had enough omograft 
material available to be able to use it with these kinds of 
intracardiac reconstructions. Homograft material may be 
a reasonable substitute, but autologous pericardium works 
well and is my preference. 
Appendix I. Preoperative and operative variables 
No. of %of 
No. of in-hospital in-hospital P 
patients deaths deaths value 
Previous operation 
Endocarditis 
No 116 17 14.7 0.365 
Yes 30 2 6.7 
Locafion of prosthesis 
Aortic 96 14 14.6 0.815 
Mitral 30 3 10.0 
Multiple 20 2 10.0 
CABG 
No 122 14 ll.5 
Yes 24 5 20.8 0.315 
No. Of operations 
1 115 16 13.9 
2 21 1 4.8 
>3 10 2 20.0 0.378 
Valve type 
Mechanical 53 8 15.1 0.751 
Biological 90 11 12.2 
Hnmograft 3 0 0 
PVE illness 
Interval between initial 
-<1 yr 117 19 16.2 
>1 yr 29 0 0.0 0.014 
Congestive heart failure 
No 41 4 9.8 
Yes 105 15 14.3 0.465 
Fever 
No >3 days 118 12 I0.2 
Yes 1-3 days 28 7 25.0 0.056 
Blond culture 
No 40 4 10.0 
Yes 106 15 14.0 0.117 
Preoperative morbidity 
No 125 14 88.8 0.154 
Yes 21 5 76.2 
PVE operation 
Gender 
Male 100 15 14.2 0.500 
Female 40 4 10.0 
Age 
<40 23 2 8.7 
40-70 99 14 14.1 0.931 
>70 24 3 12.5 
Year of operation 
1975-1984 44 9 20.4 0.079 
1985-1992 102 10 9.8 
Time between operations 
<1 yr 46 7 15.3 0.591 
>1 yr 100 12 12.0 
*Preop. morbid event 
No 35 3 8.6 
Yes 111 16 14.4 0.565 
AV block 
No 140 15 10.7 
Yes 6 4 66.7 0.003 
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Appendix I. (continued) 
No. of %of 
No. of in-hospital in-hospital P 
patients deaths deaths value 
Thromboembolism 
No 118 13 11.0 
Yes 28 6 21.4 0.206 
LV function 
Normal 102 6 5.9 
Mild 18 3 16.7 
Moderate 15 6 40.0 
Severe 6 1 16.7 0.002 
Type of operation 
Aortic 86 12 I4.3 
Mitral 31 4 12.0 
Multiple 24 2 8.3 0.778 
Nonreplacement 5 1 20.0 
Type of valve 
Biologic 76 10 13.2 
Mechanical 52 8 15:4 
Homograft i3 0 0.0 0.327 
Staph. aureus 
No 115 12 10.4 
Yes 31 7 22.6 0.127 
Fungus 
No 138 18 13.0 
Yes 8 1 12.5 0.999 
CAD 
No 115 11 9.6 
Yes 31 8 25.8 0.031 
CABG, Coronary artery bypass grafting; PVE, prosthetic valve endocardi- 
tis;AV,, atrioventricular; LV, left ventricular; CAD, coronary artery disease. 
*Preoperative morbidity includes troke, renal function, cardiac event, 
shock, myocardial infarction, and respiratory failure. 
Append ix  II. Organisms 
Early Late 
(46 patients ) (100 patients ) 
Staph. epidermidis 20 17 
Staph. aureus 11 20 
Streptococcus 5 22 
Enterococcus 1 10 
Gram negative 9 9 
Fungus 3 5 
Culture negative 2 23 
Multiple organisms 11 
